Celecoxib, which is a non-steroidal anti-inflammatory drug, inhibits the expression of CD133 in HT29 and DLD1 colorectal cancer cells via suppressing the Wnt signaling pathway [275]. The gene discussed is PROM1; the disease is colorectal cancer.